Business Context and Reporting Period
Company: International Flavors & Fragrances Inc. (IFF)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: IFF is a global leader in creating products for food, beverage, health & biosciences, and scent applications. The company operates through five reportable segments: Taste, Food Ingredients, Health & Biosciences, Scent, and Pharma Solutions (divested in May 2025). Effective January 1, 2025, the former Nourish segment was restructured into Taste and Food Ingredients.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $10,890 | $11,484 | (5)% |
| Gross Profit | $3,938 | $4,124 | (5)% |
| Gross Margin | 36.2% | 35.9% | +30 bps |
| Operating Profit (Loss) | $(382) | $766 | (150)% |
| Net Income (Loss) | $(359) | $267 | (234)% |
| Diluted EPS | $(1.41) | $1.04 | (236)% |
| Adjusted Operating EBITDA | $2,086 | $2,205 | (5)% |
| Operating Cash Flow | $850 | $1,070 | (21)% |
| Total Debt | $5,994 | $8,977 | (33)% |
| Cash & Equivalents | $590 | $471 | +25% |
Material Changes vs. Prior Period
- Segment Reorganization: The Nourish segment was split into Taste and Food Ingredients. This triggered a quantitative goodwill impairment test, resulting in a $1.153 billion impairment charge allocated to the Food Ingredients reporting unit.
- Divestitures: IFF completed the sale of the Pharma Solutions disposal group (May 1, 2025) and the Nitrocellulose business (May 9, 2025). These transactions generated significant cash proceeds but reduced reported sales and EBITDA due to the loss of full-year contributions from these units.
- Debt Reduction: Total debt decreased by approximately $3 billion, driven by the use of divestiture proceeds to repurchase $2.0 billion of senior notes and repay term loans. This resulted in a $488 million gain on extinguishment of debt.
- Legal Settlements: The company recognized a $43 million provision for U.S. class action lawsuits related to fragrance products, including a $26 million contribution to a settlement fund.
- Tax Benefit: A one-time income tax benefit of $360 million was recorded associated with a legal entity realignment project.
Guidance, Outlook, and Risks
- Capital Allocation: The company continues to focus on deleveraging, maintaining investment-grade ratings, and returning capital to shareholders. A new $500 million share repurchase program was authorized in August 2025.
- Capital Expenditures: Management expects capital spending in 2026 to be approximately 6% of sales.
- Strategic Transformation: IFF is evaluating strategic alternatives for the Food Ingredients segment, including potential divestitures. The Soy Crush, Concentrates & Lecithin business is currently classified as "held for sale."
- Key Risks:
- Antitrust Investigations: Ongoing investigations in the EU, UK, Switzerland, and Mexico regarding potential anticompetitive conduct in fragrance businesses. The U.S. DOJ investigation was closed in February 2026.
- Goodwill Impairment: Significant intangible assets ($14.3 billion) remain on the balance sheet; future impairments could materially impact profitability.
- Supply Chain & Input Costs: Exposure to raw material price volatility, geopolitical tensions, and trade tariffs.
- Cybersecurity & AI: Risks related to data breaches and the management of AI tools in operations and R&D.
Investor Verification Checklist
- Goodwill Valuation: Verify the assumptions used in the fair value assessment of the Health & Biosciences reporting unit, which had only 9% headroom above carrying value as of November 2025.
- Divestiture Proceeds: Confirm the final post-closing adjustments for the Pharma Solutions sale, which could significantly alter the total consideration received.
- Legal Exposure: Monitor the resolution of indirect purchaser class actions in the U.S. and ongoing antitrust proceedings in Europe and other jurisdictions.
- Food Ingredients Strategy: Track progress on the strategic review of the Food Ingredients segment and the potential sale of the Soy Crush, Concentrates & Lecithin business.
- Debt Covenants: Review compliance with the net debt to credit-adjusted EBITDA ratio (currently 2.59x) under the Revolving Credit Facility.